礼来口服GLP-1药物Orforglipron在ADA年会展示减重效果,但胃肠道副作用引发争议,其安全性待确认。该药正处于减肥适应症关键试验阶段,市场期待其减重数据。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.